



Role of gender in the survival outcome of acute phase of major trauma: A nationwide, population-based study

Rong-Shou Lee^{a,b}, Wen-Chi Lin^b, Dorji Harnod^c, Hsin-Chin Shih^{a,d,f,*}, Mei-Jy Jeng^{a,e,f,*}

^aInstitute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan, ROC; ^bDepartment of Critical Care, Lotung Poh-Ai Hospital, Yilan, Taiwan, ROC; ^aDepartment of Emergency and Critical Care Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan, ROC; ^aDivision of Trauma, Department of Emergency, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; ^aDepartment's Medical Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; ^bDepartment of Pediatrics, Children's Medical Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; ⁱFaculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

Abstract

Background: Animal models of trauma have shown that females have better posttraumatic survival; however, results of previous studies on the influence of gender on major trauma patients have been controversial. This study aimed to evaluate the association between gender and survival in major trauma patients.

Methods: We retrospectively analyzed patients registered in Taiwan's National Health Insurance Research Database between 2008 and 2012 with the diagnosis codes 800-939 and 950-957 (International Classification of Diseases, ninth revision, clinical modification). Data on gender, age, catastrophic illness, and new injury severity score (NISS) \geq 16 were collected for comparing patients' mortality after trauma. Propensity score matching (PSM) was performed to eliminate dissimilarities in age, comorbidities, NISS, and primary traumatic regions between the genders.

Results: Among 10 012 major trauma patients included in the study cohort, 28.8% (n = 2880) were women. The PSM patient group consisted of 50% (2876 of 5752) women. Women had a higher 30-day (15.4% of women vs 13.8% of men; p < 0.05) and hospital (16.1% of women vs 14.5% of men; p < 0.05) mortality and lower incidence rates of acute respiratory dysfunction (62.5% of women vs 65.9% of men; p < 0.005) and acute hepatic dysfunction (0.8% of women vs 2.1% of men; p < 0.001). However, the analysis of PSM patient groups showed lower mortality rates in women with moderate trauma (NISS 16–24) in the acute phase within three days (1.4% of women vs 2.7% of men, p = 0.03). Analysis of patients with an NISS of 16–24 who died within three days showed a higher NISS in women than in men (19.7 ± 2.3 vs 18.0 ±1.9, respectively, p < 0.05).

Conclusion: There is no gender difference in 30-day or hospital mortality among major trauma patients. However, women admitted for moderate major trauma had higher survival within three days of major trauma.

Keywords: Acute phase; Gender; Major trauma; Mortality; Propensity score matching

1. INTRODUCTION

Trauma is among the top 10 causes of global mortality and has contributed to more than five million annual deaths both worldwide and in our country over the past few decades.^{1,2} Despite continuous advances in prehospital and emergency department resuscitation damage control surgery and traumatic management in the last decade, brain injury, hemorrhage, sepsis, and

Journal of Chinese Medical Association. (2020) 83: 1093-1101.

Received May 19, 2020; accepted June 10, 2020.

doi: 10.1097/JCMA.00000000000399.

multiple organ dysfunction syndrome (MODS) remain the major causes of mortality in trauma patients.³⁻⁵ Reducing and improving treatment of posttrauma morbidities allows better inhospital outcomes in trauma patients.

Animal models of trauma have shown that females have better posttraumatic survival and lower morbidity of MODS and sepsis, which are attributed to the effect of their hormones.⁶⁻⁹ However, gender-related differences in posttraumatic outcomes remain unclear when compared with the well-established genderrelated advantages in mortality and incidence of complications in animal models. First, some studies failed to show the priority of survival or lower incidence of morbidities in female patients with major trauma,¹⁰⁻¹⁴ although Haider and others reported lower mortality¹⁵⁻²⁰ and incidence of sepsis or MODS^{14,21-26} in women than in men among patients with multiple major trauma. Second, Wutzlern et al²⁷ and similar studies have reported that preexisting comorbidities increase hospital mortality rates in trauma patients. However, few studies have analyzed genderbased disparities in hospital mortality and morbidities in patients with major trauma after adjusting for differences in preexisting comorbidities.²⁷⁻³³ More analyses based on large databases with preexisting comorbidities are critical for clarifying gender-related differences in outcomes in major trauma patients.

^{*}Address Correspondence. Dr. Hsin-Chin Shih, Division of Trauma, Department of Emergency, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, ROC. E-mail address: hcshih@vghtpe.gov.tw (H.-C. Shih); Dr. Mei-Jy Jeng, Department of Pediatrics, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC. E-mail address: mjjeng@vghtpe.gov.tw (M.-J. Jeng).

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

Copyright © 2020, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/)

Therefore, this retrospective analysis of data from the National Health Insurance Research Database (NHIRD) evaluated the association between gender and clinical outcomes in patients with major trauma.

2. METHODS

2.1. Data sources

The NHIRD is a nationwide population-based database derived from the National Health Insurance Program, which was implemented in March 1995 and covers almost all residents in Taiwan. The database contains all medical services claims data on outpatient, emergency, and inpatient care and is maintained by Taiwan's Health and Welfare Data Science Center of the Ministry of Health and Welfare.

2.2. Patients

Patients with a registered emergency department visit for trauma (with recorded ambulatory care expenditures on the visits file of the NHIRD) and those who were admitted to the hospital with an admission date within three days of the emergency department visit (with inpatient expenditures on the admissions file of the NHIRD with International Classification of Diseases, ninth revision, clinical modification [ICD-9-CM] main diagnosis codes



Fig. 1. Processing flow of the study cohort. The enrolled cases are trauma patients with a registry for catastrophic illness, new injury severity score (NISS) \geq 16, and matched propensity scores with age, traumatic region, NISS, and comorbidities. NHIRD = National Health Insurance Research Database

of 800-939 and 950-957 between January 2008 and December 2012) were included for this study (Figure 1). Patients younger than 15 years or older than 99 years of age or lacking data on gender in the NHIRD registry during the event were excluded. Patients with severe injuries were defined as those with the ICD-9-CM code 959.99, with major trauma rated 16 or above on the severity scale (ie, injury severity score) in the registry for catastrophic illness patient file of the NHIRD and had a new injury severity score (NISS) above 15 at admission. Propensity score matching (PSM) was performed to avoid selection biases before examining the effect of gender on the outcome (Figure 1). The Ethics Committee of Cathay General Hospital reviewed and approval this study (IRB: CGH-LP103001).

2.3. Variables

Data on the number of patients with injuries to different body regions, preinjury comorbidities, complications, medical intervention including blood transfusion volume, mechanical ventilation days, hemodialysis, and hemodialysis days were collected for outcome analysis.

Preinjury comorbidities including cerebrovascular accident (ICD-9-CM code 430-436), congestive heart failure (404.03,404.13,404.11, 404.91, 404.93, or 428), liver dysfunction or liver cirrhosis (571, 571.2, 571.5, 571.6, 070.32, V02.61, 070.54, V02.62, or 070.52), diabetes mellitus (250), chronic kidney failure (250.40, 250.42, 585, 586, 404.02, 404.03, 404.11, 404.12, 404.13, 404.91, 404.92, 404.93, 582, 581, 587, 588, 403.1, or 403.91), chronic lung disease (490, 492, 494, 496, or 493), and malignancy (140-208) were included if the outpatient diagnosis was recorded more than twice on the ambulatory care expenditures in the visits file or on the registry for catastrophic illness patient file before the injury.

The complications included pneumonia, organ dysfunction, and sepsis.^{34,35} The ICD-9-CM codes for the definition of complications are summarized in Table 1.

2.4. Main outcome measures

The primary outcomes were differences in in-hospital and 30-day mortality rates following major trauma between the matched gender groups. In-hospital mortality was determined according to the reasons for discharge in the inpatient expenditures on the admission file as death or critical ill discharge. The 30-day mortality rate was obtained from the National Register of Deaths.

2.5. Statistical analysis

Continuous variables were examined using unpaired Student's *t* tests. Categorical variables were examined using χ^2 tests and presented as percentages. Multiple logistic regression analysis was used to identify independent variables.

SAS System for Windows, version 9.3 (SAS Institute Inc., Cary, NC) was used for all data computing and statistical analyses. Stata module, the ICD Programs for Injury Categorization (ICDPIC) software version 3.0, and Stat version 12 were used to calculate the NISS of all participants. A result was considered statistically significant at p < 0.05.

PSM was used to balance age, comorbidities, and primary traumatic regions between the genders. We first estimated the propensity scores of every participant using logistic regression; thereafter, we used a one-to-one optimal matching algorithm to create new groups of different genders that resembled the varieties described above. The propensity score of a participant in the female group was matched first to one participant in the male group on eight decimal digits. If there was no match in the male group, an attempt was made to match seven decimal digits, and so on until a matching failed for four decimal digits.

3. RESULTS

3.1. Characteristics of patients

Between January 2008 and December 2012, a total of 9 937 711 patients were registered in the ambulatory care expenditures of Taiwan's NHIRD, of which 10 012 major traumatic patients met the study criteria (Fig. 1).

The study cohort consisted of 71.2% (n = 7132) male and 28.8% (n = 2880) female patients (Table 2). Mean patient age was 50.0 years, and mean NISS was 27.5; head injuries were the most common (up to 71.9%) primary diagnosis overall. The most common comorbidity was diabetes mellitus, which occurred in 10.1% (n = 1009) of all patients. A total of 68.87% (n = 6895) of all patients experienced organ dysfunction during the hospital course, with acute respiratory dysfunction being the most frequent, occurring in 64.9% (n = 6500) of all patients. Organ failure involving more than one organ was identified in 38.4% (n = 2647) of all patients with organ dysfunction. Sepsis occurred in 17.0% (n = 1700) of all patients. The mean hospital and intensive care unit (ICU) lengths of stay (LOS) were

_					
	а	Ы	е	а.	

ICD-9-CM codes for definition of complications				
Complications	ICD-9-CM codes			
All acute respiratory dysfunction				
Acute respiratory failure	96.70, 96.71., 96.72, 518.5, 518.81			
Ventilator day: more than 3 days	93.90, 93.91, 57001B, 57023B			
Acute respiratory dysfunction	Patients of all acute respiratory dysfunction other than postoperative respiratory failure			
Postoperative respiratory dysfunction	Patients of all acute respiratory dysfunction with any one of 96020C, 96021C, 96022C			
Acute renal dysfunction	39.95, 584, 580 or any one of 58001C, 58014C, 58018			
Acute hepatic dysfunction	570, 572.2, 572.4, 573.4, 573.3			
Cardiovascular dysfunction				
Shock	785.5, 458, 785,50, 785.59, 958.4, 785.51, 785.52, 404.03			
Heart failure	404.13, 404.11, 404.91, 404.93, 428			
Pneumonia	481–486			
Sepsis				
Septicemia	038			
Sepsis	995.91			
Severe sepsis	995.92 or any ICD-9-CM Codes for a bacterial or fungal infection with any acute organ dysfunction defined as above			

ICD-9-CM = international classification of disease 9th revision, clinical modification.

Table 2.

Demographic characteristics of all included patients

Variable	All	Males	Females	р
Case number	10 012	7132	2880	
Age	50 ± 20	49 ± 20	53 ± 21	< 0.001
NISS	27.5 ± 9.2	27.6 ± 9.2	27.4 ± 9.2	0.432
Trauma regions				
Head	7197 (71.9)	5082 (71.3)	2115 (73.4)	< 0.05
Spine	552 (5.5)	455 (6.4)	97 (3.4)	< 0.001
Thorax	994 (9.9)	726 (10.2)	268 (9.3)	0.186
Abdomen	648 (6.5)	456 (6.4)	192 (6.7)	0.615
Pelvis	112 (1.1)	67 (0.9)	45 (1.5)	< 0.05
Upper extremity	117 (1.2)	72 (1.0)	45 (1.6)	< 0.05
Lower extremity	392 (3.9)	274 (3.8)	118 (4.1)	0.551
Comorbidities				
Chronic neurological disease	428 (4.3)	303 (4.3)	125 (4.3)	0.837
Congestive heart failure	517 (5.3)	360 (5.1)	157 (5.5)	0.409
Chronic liver disease	472 (4.7)	362 (5.1)	110 (3.8)	< 0.05
Diabetes mellitus	1009 (10.1)	667 (9.4)	342 (11.9)	< 0.001
Chronic kidney disease	300 (3.0)	181 (2.5)	119 (4.1)	< 0.001
Chronic lung disease	329 (3.3)	248 (3.5)	81 (2.8)	0.091
Malignancy	495 (4.9)	337 (4.7)	158 (5.5)	0.112
Complications				
Acute respiratory dysfunction (all)	6500 (64.9)	4701 (65.9)	1799 (62.5)	< 0.05
Postoperative respiratory dysfunction	5399 (53.9)	3910 (54.8)	1489 (51.7)	< 0.05
Acute respiratory dysfunction	1101 (11.0)	791 (11.1)	310 (10.8)	0.636
Acute renal dysfunction	205 (2.1)	120 (1.7)	85 (3.0)	< 0.001
Acute hepatic dysfunction	174 (1.7)	151 (2.1)	23 (0.8)	< 0.001
Acute cardiovascular dysfunction	2770 (27.7)	1972 (27.7)	798 (27.7)	0.953
Single organ dysfunction	6895 (68.9)	4977 (69.8)	1918 (66.6)	< 0.05
Multiple organ dysfunction syndrome	2647 (26.4)	1897 (26.6)	750 (26.0)	0.567
Sepsis	1700 (17.0)	1267 (17.7)	433 (15.0)	< 0.05
Thirty-day mortality	1429 (14.3)	986 (13.8)	443 (15.4)	< 0.05
Hospital mortality	1497 (15.0)	1034 (14.5)	463 (16.1)	< 0.05
Blood transfusion				
Packed RBC (U)	6.3 ± 9.4	6.4 ± 9.8	6.2 ± 8.3	0.264
Packed RBC (U) ≥ 5	4269 (42.6)	2989 (41.9)	1280 (44.4)	< 0.05
Platelet phoresis, U	0.6 ± 1.8	0.6 ± 1.9	0.6 ± 1.7	0.950
Frozen plasma, U	4.7 ± 11.9	4.9 ±12.1	4.3 ± 11.3	< 0.05
Ventilator days	10.5 ± 26.5	10.8 ± 28.6	9.8 ± 20.4	0.058
RRT, d	6.4 ± 8.5	6.3 ± 8.3	6.7 ± 8.9	0.120
IRRT, d	6.4 ± 8.8	6.0 ± 8.5	7.1 ± 9.1	0.436
CRRT, d	3.7 ± 3.6	4.0 ± 3.9	2.5 ± 1.9	< 0.05
ICU LOS, d	10.2 ± 10.3	10.4 ± 10.6	9.8 ± 9.5	< 0.05
Hospital LOS, d	27.7 ± 25.1	28.1 ± 25.7	26.6 ± 23.5	< 0.05

Data are presents as n (%) or mean \pm SD.

CRRT = continuous renal replacement therapy; ICU = intensive care unit; IRRT = intermittent renal replacement therapy; LOS = length of stay; NISS = new injury severity score; RRT = renal replacement therapy.

 27.7 ± 25.1 and 10.2 ± 10.3 days, respectively. A total of 15.0% (n = 1497) of the patients died during hospitalization; 95.5% (n = 1429) died within 30 days.

We observed significant gender-based differences in age (male, 48.8 ± 19.9 years vs female, 53.1 ± 20.5 years, p < 0.001), distribution of primary traumatic body regions (head, 71.3%; spine, 6.4%; pelvis, 0.9%; and upper extremity, 1.0% in male vs head, 73.4%; spine, 3.4%; pelvis, 1.6%; and upper extremity, 1.6% in female patients; p < 0.05), and preexisting comorbidities (chronic liver disease, 5.1%; diabetes mellitus, 9.4%; and chronic kidney disease, 2.5% in male vs. chronic liver disease, 4.1% in female patients; p < 0.05).

We observed significant differences in 30-day and hospital mortality rates between the genders. Female patients had higher 30-day (15.4% of female vs 13.8% of male patients; p < 0.05)

and hospital (16.1% of female vs. 14.510% of male patients; p < 0.05) mortality rates than male patients.

The prevalence of complications including acute respiratory dysfunction (all) (65.9% of male vs 62.5% of female patients; p < 0.05), acute hepatic dysfunction (2.1% of male vs 0.8% of female patients; p < 0.001), any organ failure (69.8% of male vs 10.5% of female patients; p < 0.05), pneumonia (14.1% of male vs 10.5% of female patients; p < 0.001), and sepsis (17.7% of male vs 15.0% of female patients; p = 0.001) was higher in male than in female patients, while the prevalence of acute renal dysfunction (1.7% of male vs 3.0% of female patients; p < 0.001) was higher in male patients.

Among medical interventions, male patients received more frozen plasma transfusion units (average 4.9 \pm 12.1 vs 4.3 \pm 11.3 U, *p* < 0.05), had a higher probability of receiving more

than five units of packed red blood cell (PRBC) during transfusion, had longer durations of continuous renal replace therapy (4.0 \pm 3.9 vs 2.5 \pm 1.9 days; *p* < 0.05) and longer ICU (10.4 \pm 10.6 vs 9.8 \pm 9.5 days; *p* < 0.05) and hospital (28.1 \pm 25.7 vs 26.6 \pm 23.5 days; *p* < 0.05) LOS.

3.2. Characteristics of propensity matching patients

The PSM cohort included 5742 patients (Fig. 1), comprising 2786 female (99.9% of prematched female patients) and 2786 male (39.1% of prematched male patients) patients (Table 3). Dissimilarities in age, primary traumatic body regions, NISS, and comorbidities besides chronic liver disease were corrected in matching. No differences in 30-day or in-hospital mortality, the incidence of MODS, or therapeutic management (including blood transfusion, ventilator days, and renal replacement therapy) were observed between the genders. However, we

observed differences in the incidence of sepsis, ICU LOS, and hospital LOS.

3.3. Mortality difference between genders in the acute phase of trauma and associated factor analysis

We divided the patients according to NISS (16–24 and >24) to further analyze mortality and observed a significant gender difference in three-day mortality for NISS 16–24 (men, 2.7% vs women, 1.4%; p < 0.05; Fig. 2A). However, there was neither significant difference between male and female patients in the 7-, 14-, 30-day, or hospital mortality in these patients with a NISS 16–24 nor for 3-, 7-, 14-, 30-day, or hospital mortality in patients with a NISS > 24 (Fig. 2A and B). Additional analysis of mortality-related covariates in patients with a NISS of 16–24 who died before day 4 showed no significant difference between the genders except that women had higher NISS than men (19.8 \pm 2.3 vs 18.0 \pm 1.9, p < 0.05; Table 4).

Table 3.

Demographic characteristics of propensity score-matched patient groups*

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Variable	All	Males	Females	р																																																																																																																																																												
App53.0 \pm 20.552.9 \pm 20.553.1 \pm 20.50.742NBS27.4 \pm 9.127.4 \pm 9.027.4 \pm 9.20.806Head4259 (74.0)2146 (74.6)2113 (73.5)0.321Fined210 (3.7)113 (3.9)97 (3.4)0.261Torax521 (9.1)254 (8.8)267 (9.3)0.500Addomen373 (6.4)182 (6.3)191 (6.6)0.630Pelvis92 (1.6)47 (1.6)45 (1.6)0.834Upper extremity209 (3.6)91 (3.2)118 (4.1)0.57Cornorbidities00 (5.2)143 (5.0)157 (5.5)0.406Chronic neurological disease241 (4.2)116 (4.0)125 (4.4)0.564Comorbidities00 (5.2)143 (5.0)157 (5.5)0.406Chronic kidney disease188 (3.3)78 (2.7)110 (3.8)<0.055	 N	5752	2876	2876																																																																																																																																																													
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Ane	53.0 ± 20.5	52 9 + 20 5	53.1 ± 20.5	0 742																																																																																																																																																												
Taruma regionsEntrant and the constraint of the constraint	NISS	27 4 +9 1	27 4 + 9 0	274 + 92	0.806																																																																																																																																																												
Head4259 (74.0)2146 (74.6)2113 (73.5)0.321Spine210 (3.7)113 (3.9)9' (3.4)0.261Thorax521 (9.1)254 (8.8)267 (9.3)0.550Abdomen373 (6.4)182 (6.3)191 (6.6)0.630Delvis92 (1.6)47 (1.6)45 (1.6)0.834Upper extremity208 (6.6)91 (3.2)118 (4.1)0.057Combridities000 (5.2)143 (5.0)157 (5.5)0.406Chronic neurological disease241 (4.2)116 (4.0)125 (4.4)0.554Compestive heart failure300 (5.2)143 (5.0)157 (5.5)0.406Chronic liver disease188 (3.3)78 (2.7)110 (3.8)<0.051	Trauma regions				0.000																																																																																																																																																												
Spine210 (3.7)113 (3.9)97 (3.4)0.261Thorax521 (9.1)254 (8.8)267 (9.3)0.550Abdomen373 (6.4)182 (6.3)191 (6.6)0.630Peivis92 (1.6)47 (1.6)45 (1.6)0.834Upper extremity209 (2.6)97 (3.2)118 (4.1)0.057Comotidities0.050 (6.2)143 (5.0)157 (6.5)0.406Chronic neurological disease241 (4.2)116 (4.0)157 (6.5)0.406Chronic ineurological disease188 (3.3)78 (2.7)110 (3.8)<0.65	Head	4259 (74 0)	2146 (74 6)	2113 (73 5)	0.321																																																																																																																																																												
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Spine	210 (3 7)	113 (3 9)	97 (3.4)	0.261																																																																																																																																																												
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Thorax	521 (9.1)	254 (8.8)	267 (9.3)	0.550																																																																																																																																																												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Abdomen	373 (6.4)	182 (6.3)	191 (6.6)	0.630																																																																																																																																																												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pelvis	92 (1.6)	47 (1.6)	45 (1.6)	0.834																																																																																																																																																												
DeportDef (13)Def (13)Def (13)Def (13)Def (13)Def (13)Comorbidities209 (3.6)91 (3.2)118 (4.1)0.057Comorbidities300 (5.2)143 (5.0)157 (5.5)0.406Chronic neurological disease188 (3.3)78 (2.7)110 (3.8)<0.05	Linner extremity	88 (1.5)	43 (1.5)	45 (1.6)	0.830																																																																																																																																																												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Lower extremity	209 (3.6)	91 (3.2)	118 (4 1)	0.000																																																																																																																																																												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Comorbidities	200 (0.0)	01 (0.2)	110 (111)	0.001																																																																																																																																																												
ComparisonEnt (12)TractoryTractoryTractoryCongestive heart failure300 (5.2)143 (6.0)157 (5.5)0.406Chronic kiver disease188 (3.3)78 (2.7)110 (3.8)<0.05	Chronic neurological disease	241 (4 2)	116 (4 0)	125 (4 4)	0.554																																																																																																																																																												
Chronic IVer disease108 (3.3)78 (2.7)110 (3.8)<0.05Diabetes mellitus666 (11.9)345 (12.0)341 (11.9)0.871Chronic kidney disease240 (4.2)122 (4.2)118 (4.1)0.792Chronic lung disease146 (2.5)66 (2.3)80 (2.8)0.241Malignancy304 (5.3)146 (5.1)158 (5.5)0.479Complications	Congestive heart failure	300 (5.2)	143 (5.0)	157 (5.5)	0.004																																																																																																																																																												
Onton the description106 (E.)116 (E.)116 (E.)(E.)Diabetes mellitus686 (11.9)345 (12.0)341 (11.9)0.871Chronic kidney disease240 (4.2)122 (4.2)118 (4.1)0.792Chronic kidney disease146 (2.5)66 (2.3)80 (2.8)0.241Malignancy304 (5.3)146 (5.1)158 (5.5)0.479Complications744 (12.9)376 (13.1)368 (12.8)0.753Acute respiratory dysfunction65 (1.1)42 (1.5)23 (0.8)<0.05	Chronic liver disease	188 (3 3)	78 (2 7)	110 (3.8)	<0.05	Chronic lung disease240 (4.2)122 (4.2)118 (4.1)0.792Chronic lung disease146 (2.5)66 (2.3)80 (2.8)0.241Malignancy304 (5.3)146 (5.1)158 (5.5)0.479Complications	Diabetes mellitus	686 (11.9)	345 (12 0)	341 (11 9)	0.871	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic kidney disease	240 (4 2)	122 (4 2)	118 (4 1)	0.792	Initial angle ansatzInitial caseInitial caseInitial caseMalignancy 304 (5.3) 146 (5.1) 158 (5.5) 0.479 Complications 744 (12.9) 376 (13.1) 368 (12.8) 0.753 Acute renal dysfunction 156 (2.7) 72 (2.5) 84 (2.9) 0.330 Acute hepatic dysfunction 65 (1.1) 42 (1.5) 23 (0.8) <0.05 Acute cardiovascular dysfunction 1680 (29.2) 833 (29.0) 847 (29.5) 0.6885 Single organ dysfunction syndrome 1585 (27.6) 805 (28.0) 780 (27.1) 0.461 Sepsis 998 (17.4) 554 (19.3) 444 (15.4) <0.001 Solution and dysfunction syndrome 862 (15.0) 417 (14.5) 445 (15.5) 0.301 Hospital mortality 862 (15.0) 417 (14.5) 445 (15.5) 0.301 Blood transfusion $Packed RBC, U$ 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U > 5 2486 (43.2) 1209 (42.0) 1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.7 0.66 ± 1.7 0.66 ± 1.7 0.66 ± 1.7 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 7.0 ± 9.4	Chronic lung disease	146 (2.5)	66 (2,3)	80 (2.8)	0.241	Intergrating complicationsDef (bb)To (b	Malignancy	304 (5.3)	146 (5.1)	158 (5.5)	0.479	Acute respiratory dysfunction744 (12.9)376 (13.1)368 (12.8)0.753Acute respiratory dysfunction156 (2.7)72 (2.5)84 (2.9)0.330Acute renal dysfunction65 (1.1)42 (1.5)23 (0.8)<0.05	Complications	001(0.0)	110 (0.1)	100 (0.0)	0.110	Acute renal dysfunction111 (12.7)72 (2.5)84 (2.9)0.330Acute renal dysfunction65 (1.1)42 (1.5)23 (0.8)<0.05	Acute respiratory dysfunction	744 (12 9)	376 (13 1)	368 (12.8)	0 753	Acute hepatic dysfunction160 (1.1)42 (1.5)23 (0.8)<0.05Acute hepatic dysfunction1680 (29.2)833 (29.0)847 (29.5)0.685Single organ dysfunction2457 (42.7)1257 (43.7)1200 (41.7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute renal dysfunction	156 (2 7)	72 (2 5)	84 (2 9)	0.330	Acute cardiovascular dysfunction160 (17)11 (17)120 (41,7)0.129Acute cardiovascular dysfunction2457 (42,7)1257 (43,7)1200 (41,7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute henatic dysfunction	65 (1 1)	42 (1.5)	23 (0.8)	<0.05	Single organ dysfunction2457 (42.7)1257 (43.7)1200 (41.7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute cardiovascular dysfunction	1680 (29.2)	833 (29 0)	847 (29.5)	0.685	Los of substantialLos (L11)Los (L11) <thlos (l11)<="" th=""><thlos (l11)<="" th=""><thlos (l11)<="" th="">Los (L</thlos></thlos></thlos>	Single organ dysfunction	2457 (42.7)	1257 (43.7)	1200 (41.7)	0.129	Mathe sign bounded splates998 (17.4)563 (21.6)163 (21.7)163 (11.7)163 (11.7)30-day mortality862 (15.0)417 (14.5)445 (15.5)0.301Hospital mortality903 (15.7)440 (15.3)463 (16.1)0.405Blood transfusion903 (15.7)440 (15.3)463 (16.1)0.405Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.70.661Frozen plasma, U4.5 ± 11.74.7 ± 12.04.3 ± 11.30.235Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	Multiple organ dysfunction syndrome	1585 (27.6)	805 (28 0)	780 (27.1)	0.461	30-day mortality862 (15.0)417 (14.5)415 (15.5)0.301Hospital mortality903 (15.7)440 (15.3)463 (16.1)0.405Blood transfusion903 (15.7)440 (15.3)463 (16.1)0.405Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05	Sensis	998 (17.4)	554 (19.3)	444 (15.4)	< 0.001	Hospital mortality903 (15.7)440 (15.3)His (16.7)His (16.7)His (16.7)Blood transfusionPacked RBC, UPacked RBC, U ≥52486 (43.2)1209 (42.0)Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.80.6 ± 1.80.6 ± 1.313.3 ± 22.80.086Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	30-day mortality	862 (15.0)	417 (14.5)	445 (15.5)	0.301	Note (101)100 (101)100 (101)100 (101)100 (101)Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥ 5 2486 (43.2)1209 (42.0)1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Hospital mortality	903 (15.7)	440 (15.3)	463 (16.1)	0.405	Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05	Blood transfusion				01100	Packed RBC, U ≥ 5 2486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.70.661Frozen plasma, U4.5 ± 11.74.7 ± 12.04.3 ± 11.30.235Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator-free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	Packed RBC. U	6.29 + 9.3	6.41 + 10.2	6.19 + 8.3	0.372	Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Packed BBC, U >5	2486 (43.2)	1209 (42.0)	1277 (44.4)	0.070	Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Platelet phoresis. U	0.6 ± 1.8	0.6 + 1.8	0.6 + 1.7	0.661	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Frozen plasma, U	4.5 ± 11.7	4.7 + 12.0	4.3 ± 11.3	0.235	Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Ventilator days	14.3 ± 35.5	15.2 + 44.3	13.3 + 22.8	0.086	RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	Ventilator-free days	18.7 ± 21.2	19.4 + 22.7	18.1 +19.5	< 0.05	IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	BBT. d	6.7 + 9.1	6.7 + 9.2	6.7 + 9.0	0.988	CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	IBBT. d	7.0 + 9.4	6.8 + 9.7	7.2 + 9.2	0.823	ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	CRRT, d	3.0 ± 2.8	3.2 ± 3.1	2.4 ± 1.9	0.363	Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 < 0.001	ICU LOS. d	10.3 ± 10.6	10.8 ± 11.5	9.8 ± 9.5	< 0.001		Hospital LOS, d	27.9 ± 26.1	29.3 ± 28.4	26.6 ± 23.4	< 0.001
Chronic liver disease	188 (3 3)	78 (2 7)	110 (3.8)	<0.05																																																																																																																																																													
Chronic lung disease240 (4.2)122 (4.2)118 (4.1)0.792Chronic lung disease146 (2.5)66 (2.3)80 (2.8)0.241Malignancy304 (5.3)146 (5.1)158 (5.5)0.479Complications	Diabetes mellitus	686 (11.9)	345 (12 0)	341 (11 9)	0.871																																																																																																																																																												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic kidney disease	240 (4 2)	122 (4 2)	118 (4 1)	0.792																																																																																																																																																												
Initial angle ansatzInitial caseInitial caseInitial caseMalignancy 304 (5.3) 146 (5.1) 158 (5.5) 0.479 Complications 744 (12.9) 376 (13.1) 368 (12.8) 0.753 Acute renal dysfunction 156 (2.7) 72 (2.5) 84 (2.9) 0.330 Acute hepatic dysfunction 65 (1.1) 42 (1.5) 23 (0.8) <0.05 Acute cardiovascular dysfunction 1680 (29.2) 833 (29.0) 847 (29.5) 0.6885 Single organ dysfunction syndrome 1585 (27.6) 805 (28.0) 780 (27.1) 0.461 Sepsis 998 (17.4) 554 (19.3) 444 (15.4) <0.001 Solution and dysfunction syndrome 862 (15.0) 417 (14.5) 445 (15.5) 0.301 Hospital mortality 862 (15.0) 417 (14.5) 445 (15.5) 0.301 Blood transfusion $Packed RBC, U$ 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U > 5 2486 (43.2) 1209 (42.0) 1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.7 0.66 ± 1.7 0.66 ± 1.7 0.66 ± 1.7 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 7.0 ± 9.4	Chronic lung disease	146 (2.5)	66 (2,3)	80 (2.8)	0.241																																																																																																																																																												
Intergrating complicationsDef (bb)To (b	Malignancy	304 (5.3)	146 (5.1)	158 (5.5)	0.479																																																																																																																																																												
Acute respiratory dysfunction744 (12.9)376 (13.1)368 (12.8)0.753Acute respiratory dysfunction156 (2.7)72 (2.5)84 (2.9)0.330Acute renal dysfunction65 (1.1)42 (1.5)23 (0.8)<0.05	Complications	001(0.0)	110 (0.1)	100 (0.0)	0.110																																																																																																																																																												
Acute renal dysfunction111 (12.7)72 (2.5)84 (2.9)0.330Acute renal dysfunction65 (1.1)42 (1.5)23 (0.8)<0.05	Acute respiratory dysfunction	744 (12 9)	376 (13 1)	368 (12.8)	0 753																																																																																																																																																												
Acute hepatic dysfunction160 (1.1)42 (1.5)23 (0.8)<0.05Acute hepatic dysfunction1680 (29.2)833 (29.0)847 (29.5)0.685Single organ dysfunction2457 (42.7)1257 (43.7)1200 (41.7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute renal dysfunction	156 (2 7)	72 (2 5)	84 (2 9)	0.330																																																																																																																																																												
Acute cardiovascular dysfunction160 (17)11 (17)120 (41,7)0.129Acute cardiovascular dysfunction2457 (42,7)1257 (43,7)1200 (41,7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute henatic dysfunction	65 (1 1)	42 (1.5)	23 (0.8)	<0.05																																																																																																																																																												
Single organ dysfunction2457 (42.7)1257 (43.7)1200 (41.7)0.129Multiple organ dysfunction syndrome1585 (27.6)805 (28.0)780 (27.1)0.461Sepsis998 (17.4)554 (19.3)444 (15.4)<0.001	Acute cardiovascular dysfunction	1680 (29.2)	833 (29 0)	847 (29.5)	0.685																																																																																																																																																												
Los of substantialLos (L11)Los (L11) <thlos (l11)<="" th=""><thlos (l11)<="" th=""><thlos (l11)<="" th="">Los (L</thlos></thlos></thlos>	Single organ dysfunction	2457 (42.7)	1257 (43.7)	1200 (41.7)	0.129																																																																																																																																																												
Mathe sign bounded splates998 (17.4)563 (21.6)163 (21.7)163 (11.7)163 (11.7)30-day mortality862 (15.0)417 (14.5)445 (15.5)0.301Hospital mortality903 (15.7)440 (15.3)463 (16.1)0.405Blood transfusion903 (15.7)440 (15.3)463 (16.1)0.405Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.70.661Frozen plasma, U4.5 ± 11.74.7 ± 12.04.3 ± 11.30.235Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	Multiple organ dysfunction syndrome	1585 (27.6)	805 (28 0)	780 (27.1)	0.461																																																																																																																																																												
30-day mortality862 (15.0)417 (14.5)415 (15.5)0.301Hospital mortality903 (15.7)440 (15.3)463 (16.1)0.405Blood transfusion903 (15.7)440 (15.3)463 (16.1)0.405Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05	Sensis	998 (17.4)	554 (19.3)	444 (15.4)	< 0.001																																																																																																																																																												
Hospital mortality903 (15.7)440 (15.3)His (16.7)His (16.7)His (16.7)Blood transfusionPacked RBC, UPacked RBC, U ≥52486 (43.2)1209 (42.0)Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.80.6 ± 1.80.6 ± 1.313.3 ± 22.80.086Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	30-day mortality	862 (15.0)	417 (14.5)	445 (15.5)	0.301																																																																																																																																																												
Note (101)100 (101)100 (101)100 (101)100 (101)Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥ 5 2486 (43.2)1209 (42.0)1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Hospital mortality	903 (15.7)	440 (15.3)	463 (16.1)	0.405																																																																																																																																																												
Packed RBC, U 6.29 ± 9.3 6.41 ± 10.2 6.19 ± 8.3 0.372 Packed RBC, U ≥52486 (43.2)1209 (42.0)1277 (44.4) 0.070 Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05	Blood transfusion				01100																																																																																																																																																												
Packed RBC, U ≥ 5 2486 (43.2)1209 (42.0)1277 (44.4)0.070Platelet phoresis, U0.6 ± 1.80.6 ± 1.80.6 ± 1.70.661Frozen plasma, U4.5 ± 11.74.7 ± 12.04.3 ± 11.30.235Ventilator days14.3 ± 35.515.2 ± 44.313.3 ± 22.80.086Ventilator-free days18.7 ± 21.219.4 ± 22.718.1 ± 19.5<0.05	Packed RBC. U	6.29 + 9.3	6.41 + 10.2	6.19 + 8.3	0.372																																																																																																																																																												
Platelet phoresis, U 0.6 ± 1.8 0.6 ± 1.8 0.6 ± 1.7 0.661 Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Packed BBC, U >5	2486 (43.2)	1209 (42.0)	1277 (44.4)	0.070																																																																																																																																																												
Frozen plasma, U 4.5 ± 11.7 4.7 ± 12.0 4.3 ± 11.3 0.235 Ventilator days 14.3 ± 35.5 15.2 ± 44.3 13.3 ± 22.8 0.086 Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Platelet phoresis. U	0.6 ± 1.8	0.6 + 1.8	0.6 + 1.7	0.661																																																																																																																																																												
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Frozen plasma, U	4.5 ± 11.7	4.7 + 12.0	4.3 ± 11.3	0.235																																																																																																																																																												
Ventilator-free days 18.7 ± 21.2 19.4 ± 22.7 18.1 ± 19.5 <0.05 RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	Ventilator days	14.3 ± 35.5	15.2 + 44.3	13.3 + 22.8	0.086																																																																																																																																																												
RRT, d 6.7 ± 9.1 6.7 ± 9.2 6.7 ± 9.0 0.988 IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	Ventilator-free days	18.7 ± 21.2	19.4 + 22.7	18.1 +19.5	< 0.05																																																																																																																																																												
IRRT, d 7.0 ± 9.4 6.8 ± 9.7 7.2 ± 9.2 0.823 CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	BBT. d	6.7 + 9.1	6.7 + 9.2	6.7 + 9.0	0.988																																																																																																																																																												
CRRT, d 3.0 ± 2.8 3.2 ± 3.1 2.4 ± 1.9 0.363 ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001	IBBT. d	7.0 + 9.4	6.8 + 9.7	7.2 + 9.2	0.823																																																																																																																																																												
ICU LOS, d 10.3 ± 10.6 10.8 ± 11.5 9.8 ± 9.5 <0.001 Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 <0.001	CRRT, d	3.0 ± 2.8	3.2 ± 3.1	2.4 ± 1.9	0.363																																																																																																																																																												
Hospital LOS, d 27.9 ± 26.1 29.3 ± 28.4 26.6 ± 23.4 < 0.001	ICU LOS. d	10.3 ± 10.6	10.8 ± 11.5	9.8 ± 9.5	< 0.001																																																																																																																																																												
	Hospital LOS, d	27.9 ± 26.1	29.3 ± 28.4	26.6 ± 23.4	< 0.001																																																																																																																																																												

Data are presented as n (%) or mean \pm SD.

CRRT = continuous renal replacement therapy; ICU = intensive care unit; IRRT = intermittent renal replacement therapy; LOS = length of stay; NISS = new injury severity score; RRT = renal replacement therapy.

*Propensity score matching for eliminating dissimilarity in age, comorbidities, and primary traumatic regions between different genders.



Fig. 2. Mortality case numbers of male and female patients during the first 60 days after trauma. A, Mortality case numbers with new injury severity score (NISS) 16 to 24 during the first 60 days after trauma. B, Mortality case numbers with NISS > 24 during the first 60 days after trauma. *p < 0.05 compared to male group of the same time period. ICD-9-CM = international classification of disease 9th revision, clinical modification.

4. DISCUSSION

Previous studies have reported lower 30-day and in-hospital mortality rates in post–major trauma hospitalized women and women of pre-menopause age than in men.^{15–20} However, other studies did not report this difference.^{10–13} Among studies reporting lower mortality rates in hospitalized female patients with major trauma, some did not assess the significance of the variables of post-grouping (age, injured body region, or injury severity)^{15,16,19,24} and others did not adjust for preexisting comorbidities in their patient cohort.^{15,16,18,20} Preexisting comorbidities including congestive heart failure, chronic obstructive pulmonary disease, asthma, hepatitis and liver cirrhosis, malignancy, and chronic kidney disease are associated with clinical outcomes of patients with major trauma.^{27–32}

We initially divided our participants by age into pre-menopause $(15-54 \text{ years})^{36,37}$ and post-menopause (≥ 55 years) groups and observed no significant difference between gender subgroups in 30-day mortality (n = 473, 11.1% in male and n = 166, 12.4% in female patients; p < 0.05 in the pre-menopause

group; n = 513, 17.9% in male and n = 277, 18.0% in female patients in the post-menopause group) or in-hospital mortality (n = 480, 11.3% in male and n = 168, 12.5% in female patients in the pre-menopause group; n = 554, 19.3% in male and n =295, 19.2% in female patients in the post-menopause group). This finding is consistent with that reported by Harnod et al.³³ However, we observed a significant difference between the genders in mortality rates (30-day and in-hospital) after classifying all patients according to gender (n = 986, 13.8% in male and n =443, 15.4% in female patients, p < 0.05 for 30-day mortality; n = 1034, 14.5% in male and n = 463, 16.1% in female patients, p < 0.05 for in-hospital mortality). To reduce the confounding effect of the covariates listed above, we conducted PSM between these two groups, after which the difference in 30-day and inhospital mortality was not statistically significant. This finding indicates that male gender is not an independent adverse prognostic factor for long-term survival in hospitalized patients with major trauma and is consistent with results previously repor ted. 13,20,26,33,36

Table 4.

Differences in characteristics between genders in patients with new injury severity scores 16–24 and mortality during the first 3 days of hospitalization

Variable	Total	Males	Females	р
N	46	30	16	
Age		54.6 ± 22.1	52.9 ± 17.8	0.790
NISS		18.0 ±1.9	19.8 ± 2.3	< 0.05
Trauma region				
Head	39 (84.8)	25 (83.3)	14 (87.5)	0.708
Spine	0	0	0	
Thorax	0	0	0	
Abdomen	6 (13.0)	5 (16.7)	1 (6.3)	0.318
Pelvis	1 (2.2)	0	1 (6.3)	0.166
Upper extremity	0	0	0	
Lower extremity	0	0	0	
Comorbidities				
Chronic neurological disease	1 (2.2)	1 (3.3)	0	0.460
Congestive heart failure	2 (4.4)	1 (3.3)	1 (6.25)	0.644
Chronic liver disease	4 (8.7)	4 (13.3)	0	0.126
Diabetes mellitus	6 (13.0)	3 (10.0)	3 (18.8)	0.401
Chronic kidney disease	0	0	0	
Chronic lung disease	3 (6.5)	2 (6.7)	1 (6.3)	0.957
Malignancy	5 (10.9)	3 (10.0)	2 (12.5)	0.795
Sepsis	21 (45.7)	15 (50.0)	6 (37.5)	0.418
Single organ dysfunction	46 (100.0)	30 (100.0)	16 (100.0)	>0.99
Acute respiratory dysfunction	21 (45.7)	15 (50.0)	6 (37.5)	0.418
Acute renal dysfunction	1 (2.2)	1 (3.3)	0 (0.0)	0.460
Acute hepatic dysfunction	2 (4.4)	2 (6.7)	0 (0.0)	0.291
Acute cardiovascular dysfunction	36 (78.3)	23 (76.7)	13 (81.3)	0.720
Multiple organ dysfunction syndrome	25 (54.4)	19 (63.3)	6 (37.5)	0.094
Packed RBC transfusion, U		8.53 ± 12.3	4.38 ± 4.3	0.102
Frozen plasma transfusion, U		4.73 ± 7.7	2.19 ± 3.7	0.138
Postoperative respiratory dysfunction	11 (23.9)	8 (26.7)	3 (18.8)	0.549
ICU LOS, d		1.93 ± 0.9	1.94 ± 0.9	0.988
Hospital LOS, d		1.93 ± 0.9	1.75 ± 0.8	0.497
Ventilator days		2.73 ± 1.4	2.75 ± 1.3	0.969

Data are presented as mean \pm SD or n (%).

ICU = intensive care unit; LOS = length of stay; NISS = new injury severity score; RBC = red blood cell.

Further analysis of the survival rate of NISS subgroups revealed a lower mortality rate within the acute phase (before day 4) of major trauma in female patients admitted with moderate to major trauma (NISS 16–24; odds ratio = 0.51, p < 0.05). Comparison of the differences in covariates including age, NISS, injured body region, preexisting comorbidities, the incidence of postinjury MODS and sepsis, and treatment between the two groups showed a statistically significant difference in NISS; however, no other covariate was significantly different. Our finding that a significantly higher NISS in the PSM female group showed lower mortality than that in the PSM male group during the acute phase of major trauma suggests increased survival in hospitalized women with major trauma and a NISS of 16–24 during the acute period.

Oberholze et al,³⁸ Frink et al,²³ Trentzsch et al,^{17,21} and Mörs et al¹⁴ reported a lower incidence of sepsis in post–major trauma hospitalized female patients than in male patients. We also observed significant difference between the two groups in both demographic (n = 1267, 17.7% in males and n = 433, 15.0% in females, p = 0.001) and post-PSM (n = 554, 19.3% in males and n = 444, 15.4% in females, p = 0.001) data. This finding indicated a lower incidence of sepsis in hospitalized female patients with major trauma (odds ratio = 0.76, p = 0.001) within the acute phase of major trauma. Furthermore, we analyzed the incidence of sepsis between patients with a NISS of 16–24 at admission and death before hospitalization day 4 and all patients in the PSM groups throughout the hospital course and observed a significant difference (n = 21, 45.7% for NISS 16–24 and death before hospital day 4 and n = 998, 17.4% for all patients in the PSM group, p < 0.001). This finding indicated a higher incidence of sepsis in hospitalized patients within the acute phase of major trauma. This finding is in agreement with those of prior studies reporting changes in systemic interleukin (IL)-6 levels in patients with trauma. IL-6 is a proinflammatory cytokine that plays a central role in the postinjury inflammatory response, the increase of which is correlated to the trauma severity³⁸⁻⁴⁰ and the development of sepsis^{40,41} in the acute phase of trauma.

We observed no statistically significant differences in the incidence of MODS between the two groups in either the demographic (n = 1897, 26.6% in men and n = 750, 26.0% in women, p = 0.57) or the post-PSM (n = 805, 28.0% in men and n = 780, 27.1% in women, p = 0.46) data. The difference between genders remained nonsignificant even after the incidence of MODS across two age groups was surveyed (n = 1008, 23.7% in men and n = 294, 21.9% in women, p = 0.19 in the pre-menopause group and n = 889, 31.0% in men and n = 456, 29.6%, p = 0.35 in the post-menopause group). This finding is in agreement with that reported by Mörs et al.¹⁴

Our findings are discordant with those of several previous studies. These differences may be due to variability in injury severity in the enrolled cohorts.^{17,26} While other studies had cohorts comprising patients with injury severities comparable

to those in our study, they did not adjust for preexisting chronic medical conditions to address potential confounding.^{21,23,42}

The findings of the current study showed a lower number of ventilator-free days in women than in men (18.1 ± 19.5 vs 19.4±22.7 days, p < 0.05 in PSM groups), as well as lower LOS in the ICU (9.8 ± 9.5 vs 10.8 ± 11.5 days, p < 0.001, PSM groups) and hospital (26.6 ± 23.4 vs 29.3 ± 28.4 days, p < 0.001, PSM groups).

As a retrospective cohort study, our results were limited by the disadvantage inherent to its design. First, the NHIRD is a claims database, and validity of the data (technical or intentional errors for easier national health insurance reimbursement)43 could have introduced bias despite the PSM to improve the validity. Second, the NHIRD does not contain detailed records of prior diseases and medical information on patients; thus, our analysis of risk factors for outcome in major trauma patients could be incomplete, despite our identification of these diseases by outpatient diagnosis, which was recorded on the ambulatory care expenditures in the visit file or the registry for patients with catastrophic illness before the injury. Finally, the classification of the trauma severity by NISS is not the same as by injury severity score, which may result in a lack of generalizability in outcomes between admitted patients with major trauma in the Taiwanese NHIRD and other countries.

In conclusion, there was no gender-based difference in longterm mortality in hospitalized patients with major trauma; however, women who were admitted for moderate major trauma had a survival advantage in the acute phase of major trauma. Moreover, hospitalized women with major trauma had a lower incidence of sepsis and shorter ICU and hospital LOS than men.

ACKNOWLEDGMENTS

This study was supported by a grant (E105) from Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital. The authors thank the assistance of professor Li-Nien Chien for her aid in the *statistics* analysis in this study.

REFERENCES

- WHO. Global Health Observatory (GHO) data: The top 10 causes of death. 24 May 2018. Available at https://www.who.int/en/news-room/ fact-sheets/detail/the-top-10-causes- of-death. Assessed April 20, 2020.
- Ministry of Health and Welfare, Taiwan: Statistics & Publications. Taiwan Health and Welfare Report 2018. Available at https://www. mohw.gov.tw/cp-137-47558-2.html. Assessed on April 20, 2020.
- 3. Pfeifer R, Tarkin IS, Rocos B, Pape HC. Patterns of mortality and causes of death in polytrauma patients—has anything changed? *Injury* 2009;40:907–11.
- Ciriello V, Gudipati S, Stavrou PZ, Kanakaris NK, Bellamy MC, Giannoudis PV. Biomarkers predicting sepsis in polytrauma patients: Current evidence. *Injury* 2013;44:1680–92.
- 5. Fröhlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, et al; Committee on Emergency Medicine, Intensive Care and Trauma Management of the German Trauma Society Sektion NIS. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg 2014;76:921–7; discussion 927–8.
- Yang S, Hu S, Chen J, Choudhry MA, Rue LW III, Bland KI, et al. Mechanism of hepatoprotection in proestrus female rats following trauma-hemorrhage: heme oxygenase-1-derived normalization of hepatic inflammatory responses. J Leukoc Biol 2009;85:1015–26.
- Szalay L, Shimizu T, Schwacha MG, Choudhry MA, Rue LW III, Bland KI, et al. Mechanism of salutary effects of estradiol on organ function after trauma-hemorrhage: upregulation of heme oxygenase. *Am J Physiol Heart Circ Physiol* 2005;289:H92–8.
- 8. Wehrenpfennig P, Drechsler S, Weixelbaumer KM, Bahrami S, Osuchowski MF. Mouse model of posttraumatic abdominal sepsis:

- Drechsler S, Weixelbaumer K, Raeven P, Jafarmadar M, Khadem A, van Griensven M, et al. Relationship between age/gender-induced survival changes and the magnitude of inflammatory activation and organ dysfunction in post-traumatic sepsis. *PLoS One* 2012;7:e51457.
- Starnes MJ, Hadjizacharia P, Chan LS, Demetriades D. Automobile versus pedestrian injuries: does gender matter? J Emerg Med 2011;40:617-22.
- Magnotti LJ, Fischer PE, Zarzaur BL, Fabian TC, Croce MA. Impact of gender on outcomes after blunt injury: a definitive analysis of more than 36,000 trauma patients. J Am Coll Surg 2008;206:984–91.
- Sharpe JP, Magnotti LJ, Weinberg JA, Brocker JA, Schroeppel TJ, Zarzaur BL, et al. Gender disparity in ventilator-associated pneumonia following trauma: identifying risk factors for mortality. J Trauma Acute Care Surg 2014;77:161–5.
- Schoeneberg C, Kauther MD, Hussmann B, Keitel J, Schmitz D, Lendemans S. Gender-specific differences in severely injured patients between 2002 and 2011: data analysis with matched-pair analysis. *Crit Care* 2013;17:R277.
- Mörs K, Braun O, Wagner N, Auner B, Voth M, Störmann P, et al. Influence of gender on systemic IL-6 levels, complication rates and outcome after major trauma. *Immunobiology* 2016;221:904–10.
- Haider AH, Crompton JG, Chang DC, Efron DT, Haut ER, Handly N, et al. Evidence of hormonal basis for improved survival among females with trauma-associated shock: an analysis of the National Trauma Data Bank. J Trauma 2010;69:537–40.
- Zhu Z, Shang X, Qi P, Ma S. Sex-based differences in outcomes after severe injury: an analysis of blunt trauma patients in China. *Scand J Trauma Resusc Emerg Med* 2017;25:47.
- Trentzsch H, Lefering R, Nienaber U, Kraft R, Faist E, Piltz S. The role of biological sex in severely traumatized patients on outcomes: a matchedpair analysis. *Ann Surg* 2015;261:774–80.
- Petersen S, Simms ER, Guidry C, Duchesne JC. Impact of hormonal protection in blunt and penetrating trauma: a retrospective analysis of the National Trauma Data Bank. *Am Surg* 2013;79:944–51.
- Mahmood K, Eldeirawi K, Wahidi MM. Association of gender with outcomes in critically ill patients. *Crit Care* 2012;16:R92.
- George RL, McGwin G Jr, Windham ST, Melton SM, Metzger J, Chaudry IH, et al. Age-related gender differential in outcome after blunt or penetrating trauma. *Shock* 2003;19:28–32.
- Trentzsch H, Nienaber U, Behnke M, Lefering R, Piltz S. Female sex protects from organ failure and sepsis after major trauma haemorrhage. *Injury* 2014;45(Suppl 3):S20–8.
- 22. Haider AH, Crompton JG, Oyetunji T, Stevens KA, Efron DT, Kieninger AN, et al. Females have fewer complications and lower mortality following trauma than similarly injured males: a risk adjusted analysis of adults in the National Trauma Data Bank. *Surgery* 2009;146:308–15.
- Frink M, Pape HC, van Griensven M, Krettek C, Chaudry IH, Hildebrand F. Influence of sex and age on mods and cytokines after multiple injuries. *Shock* 2007;27:151–6.
- 24. Yang KC, Zhou MJ, Sperry JL, Rong L, Zhu XG, Geng L, et al. Significant sex-based outcome differences in severely injured Chinese trauma patients. *Shock* 2014;42:11–5.
- Liu T, Xie J, Yang F, Chen JJ, Li ZF, Yi CL, et al. The influence of sex on outcomes in trauma patients: a meta-analysis. *Am J Surg* 2015;210:911–21.
- Keel M, Eid K, Labler L, Seifert B, Trentz O, Ertel W. Influence of injury pattern on incidence and severity of posttraumatic inflammatory complications in severely injured patients. *Eur J Trauma Emerg Surg* 2006;**32**:387–95.
- Wutzlern S, Maegele M, Marzi I, Spanholtz T, Wafaisade A, Lefering R. Association of preexisting medical conditions with in-hospital mortality in multiple-trauma patients. J Am Coll Surg 2009;209:75–81.
- Shoko T, Shiraishi A, Kaji M, Otomo Y. Effect of pre-existing medical conditions on in-hospital mortality: analysis of 20,257 trauma patients in Japan. J Am Coll Surg 2010;211:338–46.
- 29. Peetz A, Salim A, Askari R, De Moya MA, Olufajo OA, Simon TG, et al. Association of model for end-stage liver disease score and mortality in trauma patients with chronic liver disease. *JAMA Surg* 2016;151:41–8.
- 30. Toomey A, Friedman L. Mortality in cancer patients after a fall-related injury: the impact of cancer spread and type. *Injury* 2014;45:1710–6.

- 31. Dua A, Desai S, Dua A, Charlton-Ouw K, Dongerkery SP, Patel B, et al. The impact of co-morbid conditions and insurance status on trauma patient outcomes. *Trauma* 2013;15;239–44.
- Lorelli DR, Kralovich KA, Seguin C. The impact of pre-existing endstage renal disease on survival in acutely injured trauma patients. *Am* Surg 2001;67:693–6.
- Harnod D, Chen RJ, Chang WH, Chang RE, Chang CH. Mortality factors in major trauma patients: nation-wide population-based research in Taiwan. *Int J Gerontol* 2014;8:18–21.
- 34. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303–10.
- 35. Wafaisade A, Lefering R, Bouillon B, Sakka SG, Thamm OC, Paffrath T, et al; Trauma Registry of the German Society for Trauma Surgery. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. *Crit Care Med* 2011;39:621–8.
- 36. Lopez MC, Efron PA, Ozrazgat-Baslanti T, Zhang J, Cuschieri J, Maier RV, et al. Sex-based differences in the genomic response, innate immunity, organ dysfunction, and clinical outcomes after severe blunt traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg 2016;81:478–85.

- 37. Wu HC, Lai JN, Hwang JS. Quality of life and sleep quality amongst climacteric women seeking medical advice in northern Taiwan. *Sleep Med* 2012;13:906–12.
- Oberholzer A, Keel M, Zellweger R, Steckholzer U, Trentz O, Ertel W. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. *J Trauma* 2000;48:932–7.
- Stensballe J, Christiansen M, Tønnesen E, Espersen K, Lippert FK, Rasmussen LS. The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. *Acta Anaesthesiol Scand* 2009;53:515–21.
- Almahmoud K, Namas RA, Abdul-Malak O, Zaaqoq AM, Zamora R, Zuckerbraun BS, et al. Impact of injury severity on dynamic inflammation networks following blunt trauma. *Shock* 2015;44:101–9.
- Haasper C, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. *Technol Health Care* 2010;18:89–100.
- 42. Qiao Z, Wang W, Yin L, Luo P, Greven J, Horst K, et al. Using IL-6 concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis. *Eur J Trauma Emerg Surg* 2018;44:679–87.
- Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan's National Health Insurance Research Database: past and future. *Clin Epidemiol* 2019;11:349–58.